uPA, tPA and PAI-1 mRNA expression in periretinal membranes

Purpose. Formation of periretinal membranes occurs in proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR) and includes cell migration, proliferation, extracellular matrix formation and tissue contraction, processes in which plasminogen activation (PA) system is involved. Methods. Twenty PVR, PDR or pucker membranes were examined to identify the cells with cell specific markers and to detect the expression of urokinase (uPA), tissue-type plasminogen activator (tPA) or plasminogen activator inhibitor-1 (PAI-1) by in situ hybridization and by immuno-histochemistry. Results. In PVR, uPA, tPA and PAI-1 were expressed by retinal pigment epithelial (RPE) cells, macrophages or retinal glial cells. In PDR, PA components were also expressed by endothelial cells. Semiquantitative analysis in in situ hybridization and immunohistochemistry results demonstrated no notable differences in uPA, tPA or PAI-1 expression between PDR and PVR membranes. Conclusions. We conclude that local proteolytic activation is involved in extracellular matrix production both in diabetic and non-diabetic membranes.

[1]  E. Dejuan,et al.  Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. , 1999, Investigative ophthalmology & visual science.

[2]  Z. Werb.  ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[3]  O. Carpén,et al.  Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. , 1997, Circulation.

[4]  M. Weller,et al.  Plasminogen in proliferative vitreoretinal disorders , 1997, The British journal of ophthalmology.

[5]  P. Tommila,et al.  Plasminogen activation in epiretinal membranes , 1996, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  R. Clark,et al.  Wound repair in the context of extracellular matrix. , 1994, Current opinion in cell biology.

[7]  A. Vaheri,et al.  Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion. , 1990, Cell regulation.

[8]  R. Tripathi,et al.  Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. , 1990, Experimental eye research.

[9]  P. Campochiaro,et al.  Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. , 1989, Experimental eye research.

[10]  E. Ruoslahti,et al.  Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. , 1989, The Journal of biological chemistry.

[11]  O. Matsuo.  [The regulation of fibrinolysis]. , 1989, Nihon rinsho. Japanese journal of clinical medicine.

[12]  J. Mimuro,et al.  Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. , 1989, The Journal of biological chemistry.

[13]  K. Preissner,et al.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). , 1988, The Journal of biological chemistry.

[14]  F. Blasi,et al.  Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencing , 1986, FEBS letters.

[15]  P. Verde,et al.  Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Clarkson,et al.  A HISTOPATHOLOGIC REVIEW OF 168 CASES OF PRERETINAL MEMBRANE , 1977, American journal of ophthalmology.

[17]  R. Machemer,et al.  Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). , 1975, American journal of ophthalmology.

[18]  G. A. Limb,et al.  Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. , 1999, Experimental eye research.

[19]  I. Immonen,et al.  Retinal pigment epithelial cells secrete urokinase-type plasminogen activator and its inhibitor PAI-1. , 1992, Ophthalmic research.

[20]  A. Vaheri,et al.  Directed plasminogen activation at the surface of normal and malignant cells. , 1991, Advances in cancer research.

[21]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.